Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Mosnodenvir Multiple Dose Regimens in Healthy Adults
NCT05201937Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mosnodenvir in dengue fever, sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration, Time to Reach Maximum Observed Plasma Concentration and 4 more. Started Feb 2022; status: completed.
02
Drugs
mosnodenvir
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT05201937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05201937.